Population Health Sciences, University of Bristol, Bristol, UK.
VA Connecticut Healthcare System, West Haven, CT, USA.
Lancet HIV. 2024 Mar;11(3):e176-e185. doi: 10.1016/S2352-3018(23)00272-2. Epub 2024 Jan 24.
Mortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of cause-specific mortality are evolving as the population with HIV ages. We aimed to investigate longitudinal trends in cause-specific mortality among people with HIV starting ART in Europe and North America.
In this collaborative observational cohort study, we used data from 17 European and North American HIV cohorts contributing data to the Antiretroviral Therapy Cohort Collaboration. We included data for people with HIV who started ART between 1996 and 2020 at the age of 16 years or older. Causes of death were classified into a single cause by both a clinician and an algorithm if International Classification of Diseases, Ninth Revision or Tenth Revision data were available, or independently by two clinicians. Disagreements were resolved through panel discussion. We used Poisson models to compare cause-specific mortality rates during the calendar periods 1996-99, 2000-03, 2004-07, 2008-11, 2012-15, and 2016-20, adjusted for time-updated age, CD4 count, and whether the individual was ART-naive at the start of each period.
Among 189 301 people with HIV included in this study, 16 832 (8·9%) deaths were recorded during 1 519 200 person-years of follow-up. 13 180 (78·3%) deaths were classified by cause: the most common causes were AIDS (4203 deaths; 25·0%), non-AIDS non-hepatitis malignancy (2311; 13·7%), and cardiovascular or heart-related (1403; 8·3%) mortality. The proportion of deaths due to AIDS declined from 49% during 1996-99 to 16% during 2016-20. Rates of all-cause mortality per 1000 person-years decreased from 16·8 deaths (95% CI 15·4-18·4) during 1996-99 to 7·9 deaths (7·6-8·2) during 2016-20. Rates of all-cause mortality declined with time: the average adjusted mortality rate ratio per calendar period was 0·85 (95% CI 0·84-0·86). Rates of cause-specific mortality also declined: the most pronounced reduction was for AIDS-related mortality (0·81; 0·79-0·83). There were also reductions in rates of cardiovascular-related (0·83, 0·79-0·87), liver-related (0·88, 0·84-0·93), non-AIDS infection-related (0·91, 0·86-0·96), non-AIDS-non-hepatocellular carcinoma malignancy-related (0·94, 0·90-0·97), and suicide or accident-related mortality (0·89, 0·82-0·95). Mortality rates among people who acquired HIV through injecting drug use increased in women (1·07, 1·00-1·14) and decreased slightly in men (0·96, 0·93-0·99).
Reductions of most major causes of death, particularly AIDS-related deaths among people with HIV on ART, were not seen for all subgroups. Interventions targeted at high-risk groups, substance use, and comorbidities might further increase life expectancy in people with HIV towards that in the general population.
US National Institute on Alcohol Abuse and Alcoholism.
自 1996 年广泛使用有效的抗逆转录病毒疗法(ART)以来,艾滋病毒感染者的死亡率有所下降。随着艾滋病毒感染者年龄的增长,特定病因死亡率的模式也在不断变化。本研究旨在调查在欧洲和北美开始接受 ART 的艾滋病毒感染者的特定病因死亡率的纵向趋势。
在这项合作的观察性队列研究中,我们使用了来自 17 个欧洲和北美艾滋病毒队列的数据,这些队列向抗逆转录病毒治疗队列协作组织提供了数据。我们纳入了年龄在 16 岁及以上,于 1996 年至 2020 年期间开始接受 ART 的艾滋病毒感染者的数据。死因通过临床医生和算法进行单一病因分类(如果有国际疾病分类第 9 版或第 10 版数据),或由两名临床医生独立进行分类。通过小组讨论解决分歧。我们使用泊松模型比较了在 1996-99 年、2000-03 年、2004-07 年、2008-11 年、2012-15 年和 2016-20 年期间,根据时间更新的年龄、CD4 计数以及每个时期是否为初次接受 ART,进行调整后的特定病因死亡率。
在这项研究中,纳入了 189301 名艾滋病毒感染者,在 1519200 人年的随访期间记录了 16832 例死亡。13180 例(78.3%)死亡归因于病因:最常见的死因是艾滋病(4203 例;25.0%)、非艾滋病非肝炎恶性肿瘤(2311 例;13.7%)和心血管或心脏相关(1403 例;8.3%)死亡。由于艾滋病导致的死亡比例从 1996-99 年的 49%下降到 2016-20 年的 16%。每 1000 人年的全因死亡率从 1996-99 年的 16.8 例(95%CI 15.4-18.4)下降到 2016-20 年的 7.9 例(7.6-8.2)。全因死亡率随时间下降:每个日历期间的平均调整死亡率比值为 0.85(95%CI 0.84-0.86)。特定病因死亡率也下降:艾滋病相关死亡率下降最为明显(0.81;0.79-0.83)。心血管相关死亡率(0.83;0.79-0.87)、肝脏相关死亡率(0.88;0.84-0.93)、非艾滋病感染相关死亡率(0.91;0.86-0.96)、非艾滋病非肝癌恶性肿瘤相关死亡率(0.94;0.90-0.97)和自杀或意外相关死亡率(0.89;0.82-0.95)也有所下降。通过注射吸毒感染艾滋病毒的人群的死亡率在女性中有所增加(1.07;1.00-1.14),在男性中略有下降(0.96;0.93-0.99)。
接受 ART 的艾滋病毒感染者中,大多数主要死因的死亡率,特别是艾滋病相关死亡率的下降,并未在所有亚组中出现。针对高危人群、物质使用和合并症的干预措施可能会进一步提高艾滋病毒感染者的预期寿命,使其接近普通人群。
美国国家酒精滥用和酒精中毒研究所。